SEC Tracker
Get the app

Silence Therapeutics SLN

Silence Therapeutics agrees to $6.67 per share acquisition

Item 1.01 Enters material agreement, Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Major
  1. Transaction with Merck KGaA
  2. Per share consideration of $6.67
  3. Per ADS consideration of $20.00
  4. Board recommends transaction

Written from the 8-K on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Silence Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Cardiff Oncology CRDF public float $205M, Jun 30, 2025
  2. Tvardi Therapeutics TVRD public float $207M, Jun 30, 2025
  3. Rezolute RZLT public float $204M, Dec 31, 2025
  4. Natures Sunshine Products NATR public float $211M, Jun 30, 2025
  5. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025